Kalaris Therapeutics, Inc. (KLRS)

NGM – Цена в реальном времени. Валюта: USD

4.32

+0.02 (0.47%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

4.32

0.00 (0.00%)

После закрытия: Jun 26, 2026, 4:55 PM EDT

12.06.2026

Kalaris to Present at Clinical Trials at the Summit 2026

BERKELEY HEIGHTS, N.J., June 12, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, will present Phase 1a clinical data for its lead asset, TH103, at Clinical Trials at the Summit (CTS) 2026. The presentation will feature single ascending dose results from treatment-naïve patients with Neovascular Age-Related Macular Degeneration (AMD) — one of the leading causes of vision loss worldwide. These data were recently presented at Retina World Congress 2026.

12.05.2026

Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates

Patient screening now underway in the Phase 1b/2 study with the latest drug product batch on track to be available to support upcoming dosing; preliminary data anticipated in 1H 2027 Planned Phase 3 clinical trials remain on track for 2027 year-end initiation $104.9 million in cash, cash equivalents and marketable securities as of March 31, 2026 is expected to fund operations into the fourth quarter of 2027 and through key clinical milestones BERKELEY HEIGHTS, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced financial results for the first quarter ended March 31, 2026 and provided business updates.

17.03.2026

Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates

Positive initial data reported from Phase 1a Single Ascending Dose study in nAMD in December 2025; preliminary data from ongoing Phase 1b/2 study expected in 1H 2027

19.12.2025

Kalaris Therapeutics: Phase 1a Data De-Risks The Path To 2026 Catalysts

Kalaris Therapeutics offers a differentiated approach to neovascular AMD with its lead candidate TH103, leveraging unique molecular engineering for improved efficacy and durability. KLRS's Phase 1a data showed a clinically significant 10-letter visual acuity gain and promising durability, with 31% of patients needing no rescue injection for six months. With $77M in cash and a quarterly burn of ~$12M, KLRS is funded through 2027, enabling execution through the critical Phase 1b/2 data readout expected in H2 2026.

18.12.2025

Kalaris Therapeutics: TH103 Trial Success And $50M Raise Set Stage For Growth

Kalaris Therapeutics, Inc. raised $50M post-positive TH103 trial data, strengthening its cash position to fund TH103 clinical development. KLRS reported improved Q3 '25 results, with a net loss of $11.9M and $77M in cash, supporting operations through 2027. TH103, KLRS's lead asset, showed rapid efficacy and strong safety in Phase 1a, with further Phase 1b/2 data expected in H2 '26.

17.12.2025

Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement

BERKELEY HEIGHTS, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors to sell securities in a private placement for aggregate gross proceeds of approximately $50.0 million, before deducting placement agent fees and other offering expenses.

17.12.2025

Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD

TH103 showed mean 10-letter gain in visual acuity and rapid, robust anatomic improvement at Month 1, following a single injection

Видео

No Data

There is no data to display

Пресс-релизы

12.05.2026

Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates

17.03.2026

Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates

Positive initial data reported from Phase 1a Single Ascending Dose study in nAMD in December 2025; preliminary data from ongoing Phase 1b/2 study expected in 1H 2027

17.12.2025

Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement

17.12.2025

Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD

TH103 showed mean 10-letter gain in visual acuity and rapid, robust anatomic improvement at Month 1, following a single injection

Kalaris Therapeutics, Inc. (KLRS)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Kalaris Therapeutics, Inc. (KLRS)

Kalaris to Present at Clinical Trials at the Summit 2026

Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates

Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates

Kalaris Therapeutics: Phase 1a Data De-Risks The Path To 2026 Catalysts

Kalaris Therapeutics: TH103 Trial Success And $50M Raise Set Stage For Growth

Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement

Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD

Видео

No Data

Пресс-релизы

Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates

Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates

Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement

Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD

Kalaris to Present at Clinical Trials at the Summit 2026

Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates

Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates

Kalaris Therapeutics: Phase 1a Data De-Risks The Path To 2026 Catalysts

Kalaris Therapeutics: TH103 Trial Success And $50M Raise Set Stage For Growth

Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement

Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD

Видео

No Data

Пресс-релизы

Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates

Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates

Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement

Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD

Search stocks

Kalaris Therapeutics, Inc. (KLRS)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Kalaris Therapeutics, Inc. (KLRS)

Kalaris to Present at Clinical Trials at the Summit 2026

Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates

Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates

Kalaris Therapeutics: Phase 1a Data De-Risks The Path To 2026 Catalysts

Kalaris Therapeutics: TH103 Trial Success And $50M Raise Set Stage For Growth

Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement

Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD

Видео

No Data

Пресс-релизы

Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates

Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates

Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement

Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD

Kalaris to Present at Clinical Trials at the Summit 2026

Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates

Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates

Kalaris Therapeutics: Phase 1a Data De-Risks The Path To 2026 Catalysts

Kalaris Therapeutics: TH103 Trial Success And $50M Raise Set Stage For Growth

Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement

Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD

Видео

No Data

Пресс-релизы

Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates

Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates

Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement

Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD